Page 9 - Adamm Hill News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adam Beech Nottingham-based cancer detection company Oncimmune Holdings has signed a pair of agreements for the use of its newly developed and proprietary infectious disease panel. Oncimmune previously announced the award of UK Government funding for the development and validation of an infectious disease NavigAID panel under the Immunity Profiling of patients with Covid-19 for Therapy and Triage (IMPACTT) programme. Utilising the data from this and other work, the company s current SeroTag research panel has been tailored to predict Covid-19 disease severity and therapeutic response to the virus and the effectiveness of vaccines and other repurposed therapeutics as treatment against the disease.

United kingdomLos angelesAdamm hillOncimmune holdingsRoche pharmaceuticalsUnited kingdom governmentImmunity profilingஒன்றுபட்டது கிஂக்டம்லாஸ் ஏஞ்சல்ஸ்ரோச் மருந்துகள்ஒன்றுபட்டது கிஂக்டம் அரசுநோய் எதிர்ப்பு சக்தி ப்ரோஃபைலிஂக்